Document is current
Any future updates will be listed below
-
Authors
Alsaadi, Tauofik
Almadani, Abubaker
AlRukn, Suhail
Hassan, Ali
Sarathchandran, Pournamy
Shatila, Ahmed
Szolics, Miklos
Benito, David
Ince, Soydan
Krieger, Derk W. https://orcid.org/0000-0003-2457-7333
-
Funding
Funding for this research was provided by:
This work, including publication and the journal’s Rapid Service Fee, was funded by Eli Lilly.
- License Information
-
More Information
Article History
Received: 17 July 2025
Accepted: 16 September 2025
First Online: 4 October 2025
Declarations
:
: Tauofik Alsaadi has received research grants as well as speaker and consultancy fees from Pfizer, Eli Lilly, Novartis, Lundbeck, GSK, Citi Pharmacy, Abdi Ibrahim and AbbVie. Abubaker Almadni, Suhail AlRukn, Ali Hassan, Pournamy Sarathchandran, Ahmed Shatila and Miklos Szolics have no conflicts to declare in relation to this work. David Benito was an employee of Eli Lilly during the development of this manuscript and is a minor shareholder in Eli Lilly. Soydan Ince is a full-time employee of and minor shareholders in Eli Lilly. Derk W. Krieger has received consultancy and speaker board fees from Biogen and Eli Lilly.
: This article is based on previously conducted studies and expert discussions and does not contain any new studies with human participants or animals performed by any of the authors. The study was approved and granted exempt status by the American Center for Psychiatry and Neurology Institutional Review Board (reference: ACPN_IRB_0072). All participants were aware of the study objectives and the intention to publish the findings. Consent to participate was indicated by taking part in discussions and providing votes. The independence of participants was verified based on professional credentials and consideration of potential conflicts of interest. Participants’ data were protected in accordance with applicable data protection requirements.
